Active substanceMethyl ethylpyridinolMethyl ethylpyridinol
Similar drugsTo uncover
  • Cardiocipine
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Cardiocipine
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Methyl ethylpyridinol
    solution for injections 
    ATOLL, LLC     Russia
  • Methyl ethylpyridinol
    solution for injections 
    ELLARA, LTD.     Russia
  • Methyl ethylpyridinol
    solution for injections 
    Company DEKO, LLC     Russia
  • Methyl ethylpyridinol-Eskom
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Emoticon Optics
    drops d / eye 
  • Emoxibel
    solution d / infusion 
       
  • Emoxibel
    solution for injections 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxibel
    drops d / eye 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxibel
    solution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxipine®
    drops d / eye 
  • Emoxipine
    solution w / m in / in 
  • Emoxipine
    drops d / eye 
    FARMENT FIRM, LLC     Russia
  • Emoxipine
    solution for injections 
  • Emoxipine-AKOS
    drops d / eye 
  • Emoxipine-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Dosage form: & nbspinjection
    Composition:

    Per 1 ml:

    Active substance:

    Methyl ethylpyridinol hydrochloride 10.0 mg

    Excipients:

    0.1 M hydrochloric acid solution up to pH 2.5-3.5

    Water for injection - up to 1.0 ml

    Description:
    Transparent colorless or slightly yellowish tinge solution.
    Pharmacotherapeutic group:Antioxidant
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    Pharmacodynamics:Methyl ethylpyridinol is an inhibitor of free radical processes and an antioxidant. Influences the blood coagulation system: reduces blood viscosity, inhibits platelet aggregation, lengthens the clotting time. Stabilizes the membranes of cells of blood vessels and erythrocytes, increases the resistance of red blood cells to mechanical trauma and hemolysis. Reduces the permeability of the vascular wall, increases the content of cyclic nucleotides in platelets (cyclic adenosine monophosphate and cyclic guanosine monophosphate), has fibrinolytic activity, promotes resorption of hemorrhages, improves microcirculation in the vessels of the retina and other tissues of the eye.Has retinoprotective properties, protects the retina from the damaging effect of high-intensity light.
    Pharmacokinetics:The volume of distribution is 5.2 liters. The half-life is 18 min; the total ground clearance is 0.2 l / min. Metabolised in the liver. It is excreted by the kidneys.
    Indications:As part of complex therapy:
    • subconjunctival and intraocular hemorrhages of different genesis;
    • angioretinopathy (including diabetic);
    • central and peripheral chorioretinal dystrophy;
    • thrombosis of the central vein of the retina and its branches;
    • complications of myopia;
    • angiosclerotic maculodetrophy (dry form);
    • detachment of the choroid in the postoperative period after surgery for glaucoma;
    • dystrophic diseases of the cornea;
    • trauma, burns of the cornea;
    • treatment and prevention of eye lesions with high-intensity light (laser radiation during laser coagulation).
    Contraindications:Increased individual sensitivity to the drug, children under 18 years.
    Pregnancy and lactation:Use during pregnancy and the period of breastfeeding is allowed if the benefit to the mother exceeds the potential risk to the fetus and the baby.
    Dosing and Administration:

    The drug is used as part of complex therapy.

    With subconjunctival and intraocular hemorrhages of different genesis - subconjunctival or parabulbaric by 0.5 ml once a day, the course of treatment is 10-15 days;

    With central and peripheral chorioretinal dystrophy, as well as angiosclerotic macular degeneration (dry form) - parabulbarno 0.5 ml once a day, treatment course 10-15 days;

    When thrombosis of the central vein of the retina and its branches is parabulbaric in 0.5 ml once a day, the course of treatment is 10-15 days;

    With complicated myopia - parabulbarno 0.5 ml once a day, treatment course -10-30 days, it is possible to repeat the course 2-3 times a year;

    With detachment of the choroid in patients with glaucoma in the postoperative period - parabulbar or subconjunctival 0.5-1.0 ml once every 2 days, treatment course 10 injections;

    In case of injuries and burns of the cornea of ​​the 2nd degree - parabulbarno 0.5 ml once a day, treatment course 10-15 injections;

    With dystrophic diseases of the cornea - subconjunctival 0.5 ml once a day, the course of treatment 10-30 days;

    For the protection of the retina in the case of laserocoagulation (including with limiting and destructive coagulation of tumors) - parabulbar according to0.5-1.0 ml of a 1% solution (5-10 mg) for 24 hours and 1 hour prior to coagulation; then in the same doses (0.5 ml of 1% solution) once a day for 2-10 days.

    Side effects:

    From the cardiovascular system: increase in blood pressure.

    From the nervous system: short-term agitation, drowsiness.

    Allergic reactions: skin rashes, itching, swelling, flaking of the skin, hyperemia, theme.

    Other: local reactions - pain, burning, itching, hyperemia, densification, paraorbital tissues (resolves itself).

    Overdose:Overdose may increase the severity of the side effects of the drug. Symptoms: increased blood pressure, agitation and drowsiness, headache, pain in the heart, nausea, discomfort in the epigastric region, possibly a clotting disorder.
    Interaction:Do not mix Methyl ethylpyridinol in one syringe with other medications (not pharmaceutically compatible with other drugs).
    Special instructions:Treatment with methylethylpyridinol should be carried out under the control of blood pressure and blood coagulability.
    Effect on the ability to drive transp. cf. and fur:In case of development of drowsiness, it is necessary to refrain from controlling vehicles and other moving mechanisms, as well as to be cautious when carrying out potentially dangerous activities requiring increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:Solution for injection 10 mg / ml.
    Packaging:

    1 ml per ampoule of neutral glass or glass with resistance class hydrolysis HGA1.

    5 ampoules are placed in a contiguous cell pack of a polyvinylchloride (PVC) film or a polyethylene terephthalate (PET) film.

    1 or 2 contour mesh packages together with the instruction for use and the ampoule scarifier are placed in a pack of cardboard for consumer containers.

    5 or 10 ampoules together with the instruction for use and the ampoule scarifier are placed in a pack of cardboard for consumer packaging with a corrugated liner. When packing ampoules with a dot or a ring of fracture, the ampoule scaper is not inserted.

    Packing for hospitals

    4, 5 or 10 contour mesh packages together with instructions for use in an amount equal to the number of contour mesh packages are placed in a pack of cardboard for consumer containers.

    50 or 100 contour mesh packages together with an equal number of instructions for use are placed in a box of corrugated cardboard.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:
    3 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-003072
    Date of registration:03.07.2015 / 28.04.2017
    Expiration Date:03.07.2020
    The owner of the registration certificate:ELLARA, LTD. ELLARA, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp08.05.2018
    Illustrated instructions
      Instructions
      Up